Stevens, Joseph
Tezel, Oğuzhan
Bonnefil, Valentina
Hapstack, Matthew
Atreya, Mihir R.
Funding for this research was provided by:
National Institute of General Medical Sciences (R21GM150093)
Cincinnati Children's Research Foundation (Procter K-to-R Transition Award)
Article History
Received: 9 March 2024
Accepted: 17 May 2024
First Online: 29 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: Cincinnati Children’s Hospital Medical Center (CCHMC) and the estate of the late Dr. Hector R. Wong hold patents for the pediatric sepsis biomarker risk model (PERSEVERE) for risk-stratification of pediatric sepsis patients and gene-expression based adaptive endotypes. M.R.A and CCHMC hold provisional patents for provisional patents (1) for a unified biomarker model – PERSEVERENCE that incorporates PERSEVERE and endothelial dysfunction markers to predict risk of multiple organ dysfunctions in sepsis, (2) a provisional patent for a PERSEVERENCE SA-AKI model that incorporates endothelial biomarkers predictive of persistent sepsis associated acute kidney injury for enrichment in clinical trials, and (3) a provisional patent for gene-expression-based multiple organ dysfunction syndrome (MODS) subclass identification, reflective of the host innate immune response.